In re Clinton S.

2016 IL App (2d) 151138, 78 N.E.3d 413
CourtAppellate Court of Illinois
DecidedDecember 2, 2016
Docket2-15-1138
StatusUnpublished
Cited by1 cases

This text of 2016 IL App (2d) 151138 (In re Clinton S.) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Clinton S., 2016 IL App (2d) 151138, 78 N.E.3d 413 (Ill. Ct. App. 2016).

Opinion

2016 IL App (2d) 151138

No. 2-15-1138

Opinion filed December 2, 2016

______________________________________________________________________________

IN THE

APPELLATE COURT OF ILLINOIS

SECOND DISTRICT

______________________________________________________________________________

In re CLINTON S., Alleged to be a Person ) Appeal from the Circuit Court Subject to Involuntary Administration of ) of Kane County. Psychotropic Medication ) ) ) No. 15-MH-88 ) (The People of the State of Illinois, ) Honorable Petitioner-Appellee, v. Clinton S., ) Divya Sarang, Respondent-Appellant). ) Judge, Presiding. ______________________________________________________________________________

JUSTICE HUTCHINSON delivered the judgment of the court, with opinion. Justices Birkett and Spence concurred in the judgment and opinion.

OPINION

¶1 Respondent, Clinton S., had a long history of mental health issues. He had also been

diagnosed with end-stage kidney failure. In granting a petition for the involuntary

administration of psychotropic medication pursuant to section 2-107.1 of the Mental Health and

Developmental Disabilities Code (Mental Health Code) (405 ILCS 5/2-107.1 (West 2014)), the

trial court also ordered that respondent undergo regular hemodialysis treatments. This was based

on evidence that hemodialysis was essential for the safe and effective administration of the

medication, as respondent’s kidneys could not otherwise filter the chemicals from his blood.

Respondent appeals, arguing that: (1) the State failed to prove by clear and convincing evidence

that the benefits of the medication outweighed the harm; and (2) the trial court’s order exceeded

the scope of the testing and other procedures that are authorized under section 2-107.1. We

affirm.

¶2 I. BACKGROUND

¶3 Respondent was admitted to the Elgin Mental Health Center (EMHC) on February 5,

2015, after being found unfit to stand trial on a robbery charge. He had been hospitalized for

issues related to his mental health over 40 times since 1980. At the time of these proceedings,

respondent was 53 years old.

¶4 On July 23, 2015, the State filed a petition for the involuntary administration of

psychotropic medication pursuant to section 2-107.1 of the Mental Health Code. Dr. Mirella

Susnjar signed the petition, as respondent’s treating psychiatrist. In addition to seeking the

involuntary administration of several medications, Susnjar requested that respondent be ordered to

undergo regular hemodialysis treatments, which she deemed essential for the safe and effective

administration of the requested medications. Susnjar noted that respondent was suffering from

end-stage kidney failure, and she asserted that hemodialysis was necessary to prolong his life.1

¶5 The trial court conducted a hearing on the petition on August 21, 2015. Susnjar was the

only witness to testify. The parties stipulated that Susnjar was an expert in the field of psychiatry.

Susnjar testified that she had performed a psychiatric evaluation on respondent and had diagnosed

him with schizophrenia. Susnjar explained that respondent suffered hallucinations and

1 The Mayo Clinic website describes “hemodialysis” as a procedure used for the treatment

of advanced kidney failure, in which a machine is used to filter wastes, salts, and fluid from the

blood. Hemodialysis, Mayo Clinic, http:www.mayoclinic.org/tests-procedures/hemodialysis/

home/ovc-20229742 (last visited Nov. 3, 2016).

-2­ 2016 IL App (2d) 151138

delusions, heard voices, talked to himself, and struggled to converse with other people.

Respondent also occasionally became angry and violent. In one instance, he threw a food tray

and threatened to kill a nurse. Susnjar testified that respondent’s symptoms had not improved

from less restrictive treatments such as “one-to-one” and group therapies. She did not believe

that respondent was likely to stabilize without psychotropic medication. She had checked

respondent’s medical records and consulted with his assigned social worker, but she was unable

to determine whether respondent had executed a power of attorney for health care or a

declaration under the Mental Health Treatment Preference Declaration Act (755 ILCS 43/1 et

seq. (West 2014)).

¶6 Susnjar testified that respondent had previously agreed to take Stelazine (trifluoperazine),

Haldol (haloperidol), Benadryl (diphenhydramine), and lorazepam. When he took these

medications, his symptoms improved. He was able to plan and discuss his legal and health

situations. However, he eventually stopped taking the medications due to his preference for

“white” Stelazine. Susnjar explained that the EMHC offered only “purple” Stelazine. Beyond

the color, the medications were the same. After respondent stopped taking his medications, his

symptoms returned.

¶7 To treat respondent’s mood and psychosis, Susnjar sought to administer specified doses

of trifluoperazine, risperidone, quetiapine, and aripiprazole. Susnjar testified that the side

effects of the medications included neuroleptic malignant syndrome, involuntary movements,

lower blood pressure, sedation, muscle rigidity, tardive dyskinesia, diabetes, weight gain, and

cataracts. The primary benefits of the medications were that respondent would become calm

and better able to express himself and make decisions.

-3­ 2016 IL App (2d) 151138

¶8 Susnjar also petitioned for the administration of five alternative medications: haloperidol,

fluphenazine, lorazepam, diphenhydramine, and benztropine. She testified that haloperidol and

fluphenazine were alternative psychotropic medications for the treatment of psychosis and

delirium and that they involved similar side effects and benefits as the primary psychotropic

medications. Lorazepam would be used if necessary to treat anxiety; the potential side effects

were sedation and addiction. Finally, diphenhydramine and benztropine were used to treat the

side effects from the psychotropic medications. The risks included weight gain, confusion, dry

mouth, constipation, and difficulty urinating.

¶9 Susnjar also testified at length about respondent’s kidney disease and her request for

hemodialysis treatments. She explained that respondent was admitted to Sherman Hospital for

renal failure in April 2015. When respondent was discharged in May 2015, his treating

nephrologist diagnosed him with end-stage kidney failure and recommended that he undergo

hemodialysis treatments three times per week. Respondent initially received 18 hemodialysis

treatments without incident, but he later began refusing the treatments. These refusals

happened around the same time that respondent began refusing to take the psychotropic

medications. Susnjar testified that she had repeatedly discussed with respondent the status of

his kidneys and the need for hemodialysis, but respondent insisted that it was not necessary.

Based on these facts, Susnjar opined that respondent’s mental illness was directly related to his

refusal to undergo hemodialysis. Although Susnjar refrained from speculating on a specific

time frame, she opined that respondent would eventually die if he did not receive hemodialysis.

Susnjar further opined that the hemodialysis was necessary for the safe and effective

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Clinton S.
2016 IL App (2d) 151138 (Appellate Court of Illinois, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
2016 IL App (2d) 151138, 78 N.E.3d 413, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-clinton-s-illappct-2016.